Nxera Pharma Secures $8.6M Milestone from Centessa as Lilly-Owned Pipeline Advances — Nxera Pharma Co., Ltd.

Event summary

Nxera Pharma to receive $8.6M milestone payment from Centessa Pharmaceuticals (now owned by Eli Lilly) for progress in OX2R agonist pipeline development.
Payment triggered by late-stage development milestone, recognized as Q3 2026 revenue.
Nxera retains rights to future milestones and royalties from the OX2R agonist programs.
Lilly completed acquisition of Centessa on June 24, 2026, gaining control of the OX2R agonist pipeline.

The big picture

This milestone payment underscores the strategic value of Nxera's partnership with Centessa, now under Lilly's ownership. The OX2R agonist pipeline targets a broad range of sleep and neurological disorders, positioning Nxera to benefit from potential blockbuster therapies. Lilly's acquisition of Centessa signals confidence in the pipeline's commercial potential, though integration risks remain. The deal size and milestone structure highlight the high-stakes nature of late-stage biopharma development.

What we're watching

Pipeline Progress: The pace at which Centessa's OX2R agonist pipeline advances through clinical stages will determine Nxera's future milestone payments and royalty streams.
Lilly Integration: How Lilly integrates Centessa's pipeline into its own R&D strategy could impact the development timeline and commercial potential of the OX2R agonists.
Market Potential: Whether the OX2R agonist portfolio can address unmet needs in sleep-wake regulation and neurological disorders at scale will be critical for long-term value creation.